Market research
NVIV InVivo Therapeutics Holdings Corp
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 996K
- P/E ratio
- Not available
- Analyst target
- 37.5
- Dividend yield
- Not available
- Beta
- 0.66
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US46186M6057
- Market cap
- 996K
- P/E ratio
- Not available
- Analyst target
- 37.5
- Dividend yield
- Not available
- Beta
- 0.66
About
About InVivo Therapeutics Holdings Corp
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NVIV discussion.
5 years, 4 months ago
InVivo Therapeutics Holdings Corp is currently in a long term downtrend where the price is trading 27.2% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
InVivo Therapeutics Holdings Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 35.0% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 1.8% to $-2M since the same quarter in the previous year.
Based on the above factors, InVivo Therapeutics Holdings Corp gets an overall score of 2/5.